Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.
|Poll|August 8, 2014
Mediastinal Mass Found in 7-Year-Old Patient
Author(s)Cesar A. Moran, MD
A 7-year-old patient is found to have a posterior mediastinal mass. Surgical resection of the mass is performed. What is your diagnosis?
Advertisement
Advertisement
Related to this article
Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.
Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.
Adult T-cell lymphoma and leukemia may warrant upfront allogeneic transplant, according to Mary Jo Lechowicz, MD.
Poster presentations at SOHO 2026 may inform multiple myeloma practice across the newly diagnosed and relapsed/refractory settings.
The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.
The OMNI-EGFR inhibitor BH-30643 produced a 45% objective response rate among patients with EGFR C797S–positive disease in the phase 1/2 SOLARA trial.
Data presented at WCLC 2026 support the use of B7-H3–directed antibody drug conjugates and brain MRI surveillance in small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
2
WCLC 2026: How Will The Small Cell Lung Cancer Paradigm Change?
3
Novel Macrocyclic EGFR TKI Shows Responses in EGFR C797S–Positive NSCLC
4
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
5